LEXICON PHARMACEUTICALS INC (LXRX) Stock Price, Quote, News and Overview
NASDAQ:LXRX - Nasdaq - US5288723027 - Common Stock
LXRX Quote and Key Statistics
LEXICON PHARMACEUTICALS INC
NASDAQ:LXRX (1/21/2025, 8:12:52 PM)
Premarket: 0.8001 +0.01 (+1.5%)0.7883
+0.1 (+14.25%)
LXRX Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.39% | ||
| ROE | -121.22% | ||
| Debt/Equity | 0.56 |
LXRX Performance and Technical Analysis
LXRX Ownership and Analysts
LXRX Latest News and Analysis
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP...
Lexicon Appoints Scott Coiante as Chief Financial Officer
Lexicon Appoints Scott Coiante as Chief Financial Officer
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as...
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Confirms Previously Disclosed and Anticipated FDA Decision
About LXRX
Company Profile
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 285 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The firm pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The firm is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Company Info
LEXICON PHARMACEUTICALS INC
2445 Technology Forest Blvd, 11Th Floor
The Woodlands TEXAS 77381 US
CEO: Lonnel Coats
Employees: 285
Company Website: https://www.lexpharma.com/
Investor Relations: http://www.lexpharma.com/investors
Phone: 12818633000
LXRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |